Amgen and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback